Enterprise Value

39.73M

Cash

102M

Avg Qtr Burn

-12.56M

Short % of Float

9.13%

Insider Ownership

8.28%

Institutional Own.

33.60%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
DKN-01 (+/- Paclitaxel) Details
Cancer, Carcinosarcoma, Ovarian cancer, Endometrial cancer

Phase 3

Update

Phase 2

Data readout

DKN-01 (+ tislelizumab +/- CAPOX) Details
Gastroesophageal junction tumors, Cancer, Gastric cancer

Phase 2a

Data readout

FL-301 Details
Cancer, Pancreatic cancer, Gastric cancer

Phase 1

Data readout

Failed

Discontinued